From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo

CAR-modified T cells show impressive results in clinical trials. However, cytokine release syndrome and “on-target, off-tumor” reactions represent most concerning side effects. To improve the safety of CAR-T cell therapy, we established a switchable CAR platform termed UniCAR system consisting of tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Albert, Susann, Arndt, Claudia, Koristka, Stefanie, Berndt, Nicole, Bergmann, Ralf, Feldmann, Anja, Schmitz, Marc, Pietzsch, Jens, Steinbach, Jörg, Bachmann, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986651/
https://www.ncbi.nlm.nih.gov/pubmed/29876011
http://dx.doi.org/10.18632/oncotarget.25390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986651/
https://www.ncbi.nlm.nih.gov/pubmed/29876011
http://dx.doi.org/10.18632/oncotarget.25390

Ejemplares similares